Opinion|Videos|April 1, 2024
Evolution of MRD Testing in Colorectal Cancer
The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
The FDA extended the review period for zanzalintinib plus atezolizumab in metastatic colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Elfetabart Drozuntecan Elicits 70% ORR Across Lines of Therapy in SCLC
2
Extended-Interval Tarlatamab Yields Comparable Exposure, Survival to Q2W Dose in Previously Treated SCLC
3
Subcutaneous Tarlatamab Safe, Active Against ES-SCLC Tumors in Phase 1B Trial
4
LCT After Nivolumab/Ipilimumab Induction Fails to Improve Metastatic NSCLC Survival
5